High-Sensitivity Cardiac Troponin On Presentation to Rule Out Myocardial Infarction

NACompletedINTERVENTIONAL
Enrollment

31,492

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

January 2, 2017

Study Completion Date

December 2, 2021

Conditions
Acute Coronary SyndromeMyocardial Infarction
Interventions
OTHER

Validation Phase

Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.

OTHER

Randomization Phase

Standard care or HighSTEACS pathway.

OTHER

Implementation Phase

Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are \<5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (\<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.

All Listed Sponsors
collaborator

NHS Lothian

OTHER_GOV

collaborator

NHS Greater Glasgow and Clyde

OTHER

lead

University of Edinburgh

OTHER

NCT03005158 - High-Sensitivity Cardiac Troponin On Presentation to Rule Out Myocardial Infarction | Biotech Hunter | Biotech Hunter